Literature DB >> 8275169

Generalizability of valuations on health states collected with the EuroQolc-questionnaire.

M L Essink-Bot1, M E Stouthard, G J Bonsel.   

Abstract

PROBLEM: Non-response and non-usable response were found in population surveys on valuation of health states. If non-response is selective regarding valuations, then generalization of the resulting values to the whole survey population is not permitted. This could limit the use of empirical utility values in resource allocation in health care.
METHODS: Response behaviour of a sample of 1400 from the Dutch general population to the mailed EuroQolc-questionnaire was analyzed by four methods. I. Phoning resolute non-respondents; II. comparison of zip code characteristics of respondents and non-respondents (because individual data on background characteristics were not available for the non-respondents); III. analysis of response over time (wave-analysis); IV: comparison of background variables of successful (less than two valuations missing) and unsuccessful respondents, combined with analysis of the effect of these background variables on valuations.
RESULTS: No indications for selective non-response were found, although the phenomenon appeared hard to investigate. The successful response came from a slightly younger and better educated subsample. However, a general influence of age and educational level on valuations could not be shown. This finding is consistent with the literature.
CONCLUSION: Although the existence of selective non-response cannot be excluded, its relevance can be considered to be small. This finding is encouraging for the use of empirical utility values in allocative decisions.

Entities:  

Mesh:

Year:  1993        PMID: 8275169     DOI: 10.1002/hec.4730020307

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  40 in total

1.  A population comparison of participants and nonparticipants in a health survey.

Authors:  R C Klesges; J E Williamson; G W Somes; G W Talcott; H A Lando; C K Haddock
Journal:  Am J Public Health       Date:  1999-08       Impact factor: 9.308

2.  Culture, self-rated health and resource allocation decision-making.

Authors:  V L Wiseman
Journal:  Health Care Anal       Date:  1999

3.  Valuation of EuroQOL (EQ-5D) health states in an adult US sample.

Authors:  J A Johnson; S J Coons; A Ergo; G Szava-Kovats
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

4.  [Economic aspects of ambulatory and inpatient treatment of HIV positive patients].

Authors:  M Stoll; R E Schmidt
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

5.  Validation of the KDQOL-SF: a dialysis-targeted health measure.

Authors:  J C Korevaar; M P Merkus; M A M Jansen; F W Dekker; E W Boeschoten; R T Krediet
Journal:  Qual Life Res       Date:  2002-08       Impact factor: 4.147

6.  Understanding health state valuations: a qualitative analysis of respondents' comments.

Authors:  Nancy J Devlin; Paul Hansen; Caroline Selai
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

7.  Using the effect size to model change in preference values from descriptive health status.

Authors:  Kristy Sanderson; Gavin Andrews; Justine Corry; Helen Lapsley
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

8.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

Review 9.  Multi-attribute health status classification systems. Health Utilities Index.

Authors:  D Feeny; W Furlong; M Boyle; G W Torrance
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

Review 10.  Multi-attribute preference functions. Health Utilities Index.

Authors:  G W Torrance; W Furlong; D Feeny; M Boyle
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.